On tonight’s MAD MONEY show on CNBC, Cramer reviewed what the state of the stent market will be.
There is a meeting Thursday at the FDA where the FDA is going to make a recommendation or decision on stents and the approval of them. Cramer thinks that stents will stay and the FDA may either ask for more data or just make token comments.
Both Boston Scientific (BSX) & J&J (JNJ) have been down on the possibility that an FDA decision "could" go against them. Cramer said that BSX is the riskier of the two because it has more business leveraged, and JNJ has diversified mush of its operations. Cramer prefers BSX for a trade, but warned again that this has risks.BSX traded up almost 4% today to $16.56, but traded up another 0.9% to$16.70 after Cramer discussed this.
By the way, Cramer left off two important companies here. SurModics (SRDX) provides the stent polymer coating for J&J and Angiotech (ANPI) makes the stent polymer coating for Boston Scientific. Those would both be very leveraged, with more downside if FDA pans the stent markets.
Jon C. Ogg
December 5, 2006
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
